Mutagenic and carcinogenic potency determinations for NDMA support the cumulative dose assumption underpinning the less-than-lifetime Threshold of Toxicological Concern
Archives of Toxicology · 2026
DOI: 10.1007/s00204-026-04385-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Toxicology, 2026. Verfasst von John W Wills und 5 weiteren Autor:innen. Beteiligte Einrichtung: Non-Clinical Safety, GSK R&D Stevenage, Stevenage, UK. john.w.wills@gsk.com. Hauptthemen laut MEDLINE: Dimethylnitrosamine, Carcinogens, Mutagens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The management of N-nitrosamine impurities challenges pharmaceutical development and regulation worldwide. Because most medicinal exposures are shorter than lifetime and absolute impurity exclusion is impossible, reliable approaches to define duration-specific intake limits are essential. On the premise that carcinogenic risk is proportional to cumulative dose, the 'Less-Than-Lifetime' (LTL) Threshold of Toxicological Concern (TTC) framework defines progressively lower intake limits for mutagenic impurities over longer exposures. However, N-nitrosamines are currently treated as a 'cohort of concern', necessitating compound-specific evaluation placing reliance on in vivo mutagenicity assays for impurity qualifications. To better understand durational potency relationships and the application domain of the LTL-TTC, we applied benchmark dose (BMD) modelling to cumulative-dose-scaled transgenic rodent (TGR), error-corrected sequencing and rodent carcinogenicity datasets for N-nitrosodimethylamine (NDMA) obtained from the published literature. For TGR, cumulative-dose scaling better resolved liver as the most sensitive organ and reduced interstudy variability: liver BMDs spanned ~ 80-fold in daily-dose units but only ~ 20-fold when scaled to cumulative dose. Among closely-matched mouse liver gavage studies, cumulative-dose BMDs only varied by ~ 2.5-fold across 1 to 28-day treatment regimens. Error-corrected sequencing also demonstrated parity, with acute-dose regimens producing mutation burdens near-identical (< 1.2-fold) to those cumulated from 28-day repeat-dose regimens. Comparable results were obtained from carcinogenicity datasets confirming proportionality-of-effect to cumulative dose. These findings empirically support the validity of the LTL-TTC concept. More broadly, they demonstrate that short-term in vivo mutagenicity assays can serve as reliable surrogates for lifetime carcinogenicity studies, strengthening the scientific and regulatory basis for duration-adjusted acceptable intakes for N-nitrosamine impurities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Non-Clinical Safety, GSK R&D Stevenage, Stevenage, UK. john.w.wills@gsk.com.
- Non-Clinical Safety, GSK R&D Stevenage, Stevenage, UK.
- Occupational and Product Quality Toxicology, GSC Engineering and Global EHS, Stevenage, UK.
- Non-Clinical Safety, GSK R&D Stevenage, Stevenage, UK. anthony.m.lynch@gsk.com.
ORCID-Profile: John W Wills
Zitieren
APA
Wills, J. W., White, A., Harte, D. S. G., Buckley, R., Harvey, J. S., & Lynch, A. M. (2026). Mutagenic and carcinogenic potency determinations for NDMA support the cumulative dose assumption underpinning the less-than-lifetime Threshold of Toxicological Concern. Archives of Toxicology. https://doi.org/10.1007/s00204-026-04385-0
Vancouver
Wills JW, White A, Harte DSG, Buckley R, Harvey JS, Lynch AM. Mutagenic and carcinogenic potency determinations for NDMA support the cumulative dose assumption underpinning the less-than-lifetime Threshold of Toxicological Concern. Archives of Toxicology. 2026. doi:10.1007/s00204-026-04385-0
BibTeX
@article{Wills2026,
author = {Wills, John W and White, Angela and Harte, Danielle S G and Buckley, Ruby and Harvey, James S and Lynch, Anthony M},
title = {Mutagenic and carcinogenic potency determinations for NDMA support the cumulative dose assumption underpinning the less-than-lifetime Threshold of Toxicological Concern},
journal = {Archives of Toxicology},
year = {2026},
doi = {10.1007/s00204-026-04385-0}
}
EUVIMED